Flipper, you're right in my case. And, I'm pretty long of tooth here. We're talking sabertooth long. While reading all the posts with posters' price estimates post good news, I have to admit - it's refreshing change from a lot of the other chatter.
Here's a point of information for other long-toothed friends: When the share price exceeded 12.00 a share back in July, 2015, there were approx. 78M shares outstanding. Today, depending on whose count you believe, there are roughly 325M shares and we're at .17. So, trying to make something at least entertaining out of this, that 12.00 of 2015 would be about the same MC as hitting 3.00 today. And since we're playing this game, it's important to keep in mind that the 12.00 spike was due to virtually nothing! Look how much farther along we are. Look at the partnership possibilities. Other treatments need DCVax to boost efficacy to more significant numbers. Moreover, look at the costs of newer treatments. DCVax will be priced at less than half of the Kite/Gilead CAR-T just approved. And, it might be as low as 1/3 that cost.
Anyway, it's nice to see discussions about post-approval issues for a change instead of stories about why the trial is doomed.
News 
Market Data 
Discover 
